PEPG
HEALTHCAREPepGen Inc
$1.84-0.09 (-4.40%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PEPG Today?
No stock-specific AI insight has been generated for PEPG yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.01$7.80
$1.85
Fundamentals
Market Cap$128M
P/E Ratio—
EPS$-2.13
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume1.9M
Avg Volume (10D)—
Shares Outstanding69.2M
PEPG News
21 articles- Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - Drug Sales, Patent, Price, Dosage, Proprietary Technologies & OutlookGlobeNewswire Inc.·Apr 21, 2026
- PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort UnderwayMarketbeat·Apr 1, 2026
- PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT DataYahoo Finance·Mar 30, 2026
- PepGen muscular dystrophy drug gets ‘surprise’ hold from FDABiopharmadive·Mar 5, 2026
- PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate HighlightsYahoo Finance·Mar 4, 2026
- PepGen Announces Regulatory Updates on FREEDOM2Yahoo Finance·Mar 4, 2026
- PepGen to Participate in the Leerink Global Healthcare ConferenceYahoo Finance·Mar 3, 2026
- How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44%Yahoo Finance·Dec 10, 2025
- PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal OfficerYahoo Finance·Dec 9, 2025
- PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal OfficerYahoo Finance·Dec 8, 2025
- Sarepta's Stock Rises on Positive Updates on DM1 TherapyYahoo Finance·Nov 25, 2025
- PepGen Inc.'s (NASDAQ:PEPG) largest shareholders are individual investors with 39% ownership, private equity firms own 36%Yahoo Finance·Nov 15, 2025
- PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 MoleculeYahoo Finance·Nov 12, 2025
- PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsYahoo Finance·Nov 12, 2025
- PepGen to Participate in Upcoming Investor ConferencesYahoo Finance·Nov 3, 2025
- BofA Lifts PepGen (PEPG) PT to $3 on Positive DM1 Data Despite Underperform RatingYahoo Finance·Oct 26, 2025
- PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle SocietyYahoo Finance·Oct 2, 2025
- PepGen Inc. (PEPG) Rating Upgraded With 135% Upside on FREEDOM DataYahoo Finance·Sep 30, 2025
- A Look at PepGen (PEPG) Valuation After Positive Clinical Data and $100M Equity RaiseYahoo Finance·Sep 27, 2025
- PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesYahoo Finance·Sep 26, 2025
- PepGen (PEPG) Skyrockets 121% on Stellar Experimental Treatment Trial ResultsYahoo Finance·Sep 26, 2025
All 21 articles loaded
Price Data
Open$1.90
Previous Close$1.93
Day High$1.93
Day Low$1.68
52 Week High$7.80
52 Week Low$1.01
52-Week Range
$1.01$7.80
$1.85
Fundamentals
Market Cap$128M
P/E Ratio—
EPS$-2.13
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume1.9M
Avg Volume (10D)—
Shares Outstanding69.2M
About PepGen Inc
PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious neurological and neuromuscular diseases. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—